EGFR and non-small cell lung carcinoma: Furthermore, for even the most responsive cancers, the NSCLC, only those with gain-of-function mutations in EGFR tyrosine kinase activity respond well to TKIs, whereas cancers that express wild-type EGFR either respond poorly, or not at all23.